Definium Therapeutics, Inc.
DFTXHealthcareNASDAQBiotechnology · Last scanned Oct 24, 2026
Scan Results
Daily timeframeDefinium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The $4.79B market capitalization puts DFTX squarely in mid-cap range for its industry. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder.
Market Cap
$4.79B
Beta
2.19
P/E (TTM)
—
P/E (Fwd)
-18.38
EPS (TTM)
$-3.40
EPS (Fwd)
$-1.94
ROE
-64.1%
ROA
-20.6%
Cash
$1.08B
Total Debt
$36.5M
Free CF
$7.6M
52W Change
188.1%
Annual Financials
Cash vs Debt
Where DFTX stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, DFTX finished 1.23% above its 150-day moving average ($32.57) and 15.28% above its 200-day moving average ($28.60). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is DFTX overbought or oversold?
At the October 20, 2026 close, DFTX's RSI(14) was 29.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $1.08B in cash comfortably exceeding the $36.5M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company generates $7.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at -64.1%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
A beta of 2.19 means DFTX is more volatile than average. Investors should be prepared for wider price swings relative to broader indices. With cash comfortably exceeding debt, DFTX has financial flexibility that may help navigate uncertain periods. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Definium Therapeutics, Inc. and its sector.